{"component": "definition", "props": {"groups": [{"snippet": "means any study or data collection effort in respect to any Product for a particular Indication that is initiated after receipt of Regulatory Approval for such Product for such Indication.", "size": 19, "samples": [{"hash": "6wdx5m0F7w6", "uri": "/contracts/6wdx5m0F7w6#phase-4-study", "label": "License and Collaboration Agreement", "score": 31.340862423, "published": true}, {"hash": "3eY9s4ns64l", "uri": "/contracts/3eY9s4ns64l#phase-4-study", "label": "License and Collaboration Agreement", "score": 31.340862423, "published": true}, {"hash": "eCbXvMYhqMP", "uri": "/contracts/eCbXvMYhqMP#phase-4-study", "label": "License and Collaboration Agreement (Ziopharm Oncology Inc)", "score": 26.2484599589, "published": true}], "snippet_links": [{"key": "data-collection", "type": "clause", "offset": [19, 34]}, {"key": "in-respect-to", "type": "clause", "offset": [42, 55]}, {"key": "receipt-of-regulatory-approval", "type": "clause", "offset": [120, 150]}], "hash": "f1ac459f4efb543c852794f5d617cde1", "id": 1}, {"snippet": "means a post-marketing human clinical study for a Licensed Product with respect to any indication as to which Regulatory Approval has been received or for a use that is the subject of an investigator-initiated study program.", "size": 5, "samples": [{"hash": "8XQXSot3AyX", "uri": "/contracts/8XQXSot3AyX#phase-4-study", "label": "Exclusive License Agreement (Ablynx NV)", "score": 28.7508555784, "published": true}, {"hash": "hxGqSiI7F5T", "uri": "/contracts/hxGqSiI7F5T#phase-4-study", "label": "Exclusive License Agreement (Ablynx NV)", "score": 28.6605065024, "published": true}, {"hash": "7oTwcsEW75j", "uri": "/contracts/7oTwcsEW75j#phase-4-study", "label": "Exclusive License Agreement (Ablynx NV)", "score": 28.6057494867, "published": true}], "snippet_links": [{"key": "clinical-study", "type": "clause", "offset": [29, 43]}, {"key": "licensed-product", "type": "clause", "offset": [50, 66]}, {"key": "with-respect-to", "type": "clause", "offset": [67, 82]}, {"key": "regulatory-approval", "type": "clause", "offset": [110, 129]}, {"key": "subject-of", "type": "clause", "offset": [173, 183]}, {"key": "study-program", "type": "definition", "offset": [210, 223]}], "hash": "249ad69a419ab3f77c2220124d595886", "id": 2}, {"snippet": "means a clinical study which is carried out after Commercialization of the Product (i.e., a study that is not carried out at the request of any Regulatory Authority or in connection with obtaining or maintaining any Regulatory Approval).", "size": 5, "samples": [{"hash": "hMdRQwDovD5", "uri": "/contracts/hMdRQwDovD5#phase-4-study", "label": "Commercialization and License Agreement (Aptalis Holdings Inc.)", "score": 24.9589322382, "published": true}, {"hash": "kW52oL9HxEi", "uri": "/contracts/kW52oL9HxEi#phase-4-study", "label": "Commercialization and License Agreement (Aptalis Pharma Inc)", "score": 23.3189596167, "published": true}, {"hash": "lJ2jX87fPrL", "uri": "/contracts/lJ2jX87fPrL#phase-4-study", "label": "Commercialization and License Agreement (Aptalis Pharma Inc)", "score": 23.1081451061, "published": true}], "snippet_links": [{"key": "clinical-study", "type": "clause", "offset": [8, 22]}, {"key": "commercialization-of-the-product", "type": "clause", "offset": [50, 82]}, {"key": "the-request", "type": "clause", "offset": [125, 136]}, {"key": "regulatory-authority", "type": "definition", "offset": [144, 164]}, {"key": "in-connection-with", "type": "clause", "offset": [168, 186]}, {"key": "regulatory-approval", "type": "clause", "offset": [216, 235]}], "hash": "cce12c6092a2edf8a2b4bc1ec9117f53", "id": 3}, {"snippet": "means a post-marketing human clinical study for a Product with respect to any indication as to which Regulatory Approval has been received or for a use that is the subject of an investigator-initiated study program.", "size": 4, "samples": [{"hash": "3wo73RJbPnH", "uri": "/contracts/3wo73RJbPnH#phase-4-study", "label": "Collaboration Agreement (Galapagos Nv)", "score": 27.4147843943, "published": true}, {"hash": "ba5dwzZmfJF", "uri": "/contracts/ba5dwzZmfJF#phase-4-study", "label": "Collaboration Agreement (Galapagos Nv)", "score": 26.3388090349, "published": true}, {"hash": "3upD04oFsN", "uri": "/contracts/3upD04oFsN#phase-4-study", "label": "Collaboration Agreement (Galapagos Nv)", "score": 26.2840520192, "published": true}], "snippet_links": [{"key": "clinical-study", "type": "clause", "offset": [29, 43]}, {"key": "with-respect-to", "type": "clause", "offset": [58, 73]}, {"key": "regulatory-approval", "type": "clause", "offset": [101, 120]}, {"key": "subject-of", "type": "clause", "offset": [164, 174]}, {"key": "study-program", "type": "definition", "offset": [201, 214]}], "hash": "3e55779c9d7086374c37d27b6f7a5fd7", "id": 4}, {"snippet": "means a human clinical trial of a compound or product in patients commenced after receipt of Regulatory Approval for such compound or product, which clinical trial is conducted within the parameters of such Regulatory Approval, including clinical trials required or requested by any Regulatory Authority as a condition of, or in connection with, obtaining such Regulatory Approval of such compound or product, provided, a \u201cPhase 4 Study\u201d may also include clinical trials to gather additional information regarding such compound\u2019s or product\u2019s potential risks, medical or pharmacoeconomic benefits, justification and descriptions for other indications of such compound or product, data to be included in compendial listings, optimal use, dose, route and schedule of administration, epidemiological studies, modeling and pharmacoeconomic studies.", "size": 4, "samples": [{"hash": "cBr48DQZS4E", "uri": "/contracts/cBr48DQZS4E#phase-4-study", "label": "License, Development and Commercialization Agreement (Windtree Therapeutics Inc /De/)", "score": 36.2854209446, "published": true}, {"hash": "eHddbL5PgxP", "uri": "/contracts/eHddbL5PgxP#phase-4-study", "label": "License, Development and Commercialization Agreement (Windtree Therapeutics Inc /De/)", "score": 35.288843258, "published": true}, {"hash": "cSWHLdkZPIM", "uri": "/contracts/cSWHLdkZPIM#phase-4-study", "label": "License, Development and Commercialization Agreement (Windtree Therapeutics Inc /De/)", "score": 28.6358658453, "published": true}], "snippet_links": [{"key": "human-clinical-trial", "type": "definition", "offset": [8, 28]}, {"key": "receipt-of-regulatory-approval", "type": "clause", "offset": [82, 112]}, {"key": "clinical-trials", "type": "definition", "offset": [238, 253]}, {"key": "requested-by", "type": "definition", "offset": [266, 278]}, {"key": "regulatory-authority", "type": "definition", "offset": [283, 303]}, {"key": "condition-of", "type": "clause", "offset": [309, 321]}, {"key": "in-connection-with", "type": "clause", "offset": [326, 344]}, {"key": "approval-of", "type": "definition", "offset": [372, 383]}, {"key": "additional-information-regarding", "type": "clause", "offset": [481, 513]}, {"key": "potential-risks", "type": "definition", "offset": [543, 558]}, {"key": "other-indications", "type": "definition", "offset": [633, 650]}, {"key": "schedule-of", "type": "definition", "offset": [753, 764]}], "hash": "8daa954d4bcbb047d3126fe7f198d22f", "id": 5}, {"snippet": "means any human clinical study of Product conducted after Product receives the first Regulatory Approval, but not required by the applicable Regulatory Agency as a condition of such Regulatory Approval.", "size": 3, "samples": [{"hash": "40XWKt62dPh", "uri": "/contracts/40XWKt62dPh#phase-4-study", "label": "Development and License Agreement", "score": 31.340862423, "published": true}, {"hash": "6Ht5Brkq63", "uri": "/contracts/6Ht5Brkq63#phase-4-study", "label": "Development and License Agreement (Pfenex Inc.)", "score": 26.3059548255, "published": true}, {"hash": "6eqCYPrtfFx", "uri": "/contracts/6eqCYPrtfFx#phase-4-study", "label": "Development and License Agreement (Pfenex Inc.)", "score": 26.2840520192, "published": true}], "snippet_links": [{"key": "clinical-study", "type": "clause", "offset": [16, 30]}, {"key": "first-regulatory-approval", "type": "definition", "offset": [79, 104]}, {"key": "required-by", "type": "definition", "offset": [114, 125]}, {"key": "the-applicable", "type": "clause", "offset": [126, 140]}, {"key": "regulatory-agency", "type": "clause", "offset": [141, 158]}, {"key": "condition-of", "type": "clause", "offset": [164, 176]}], "hash": "60b9fd349b1e1d5ea52e9d8c37a1dabc", "id": 6}, {"snippet": "means (a) a human clinical trial for a Licensed Product for an Indication that is required by a Regulatory Authority as a condition of (but is not completed before) obtaining the initial Regulatory Approval for such Licensed Product for such Indication and (b) any trial, test or study that is required or requested by a Regulatory Authority as a condition of maintaining the initial Regulatory Approval for a Licensed Product for an Indication, excluding any Post Approval Study.", "size": 2, "samples": [{"hash": "g7c64e7uPYa", "uri": "/contracts/g7c64e7uPYa#phase-4-study", "label": "License Agreement (Macrogenics Inc)", "score": 24.7563312799, "published": true}, {"hash": "4313uCVX5TN", "uri": "/contracts/4313uCVX5TN#phase-4-study", "label": "License Agreement (Macrogenics Inc)", "score": 24.5838466804, "published": true}], "snippet_links": [{"key": "human-clinical-trial", "type": "definition", "offset": [12, 32]}, {"key": "licensed-product", "type": "clause", "offset": [39, 55]}, {"key": "required-by", "type": "definition", "offset": [82, 93]}, {"key": "regulatory-authority", "type": "definition", "offset": [96, 116]}, {"key": "condition-of", "type": "clause", "offset": [122, 134]}, {"key": "not-completed", "type": "clause", "offset": [143, 156]}, {"key": "initial-regulatory-approval", "type": "definition", "offset": [179, 206]}, {"key": "requested-by", "type": "definition", "offset": [306, 318]}], "hash": "9c3d35bac0a0fffbdb94a29807afe61b", "id": 7}, {"snippet": "means any clinical trial of a Licensed Product conducted after receipt of Marketing Authorization in the approved indication, which is required to maintain such Marketing Authorization or otherwise useful for Commercializing such Licensed Product.", "size": 2, "samples": [{"hash": "hGDBtHhsDpe", "uri": "/contracts/hGDBtHhsDpe#phase-4-study", "label": "Development and Commercialization Agreement (Theravance Biopharma, Inc.)", "score": 32.1540041068, "published": true}, {"hash": "6kkoICZJZSf", "uri": "/contracts/6kkoICZJZSf#phase-4-study", "label": "Development and Commercialization Agreement (Theravance Biopharma, Inc.)", "score": 26.3086926762, "published": true}], "snippet_links": [{"key": "clinical-trial", "type": "clause", "offset": [10, 24]}, {"key": "licensed-product", "type": "clause", "offset": [30, 46]}, {"key": "after-receipt-of", "type": "clause", "offset": [57, 73]}, {"key": "marketing-authorization", "type": "clause", "offset": [74, 97]}, {"key": "approved-indication", "type": "definition", "offset": [105, 124]}, {"key": "to-maintain", "type": "clause", "offset": [144, 155]}], "hash": "4a3f46a9816cafdc07ce8d469396ad91", "id": 8}, {"snippet": "means any Phase 4 Required Study or any Phase 4 Optional Study.", "size": 2, "samples": [{"hash": "bZHZ6HDj2wD", "uri": "/contracts/bZHZ6HDj2wD#phase-4-study", "label": "Collaboration and License Agreement (Sage Therapeutics, Inc.)", "score": 34.1252566735, "published": true}, {"hash": "iddK8hpS0Uu", "uri": "/contracts/iddK8hpS0Uu#phase-4-study", "label": "Collaboration and License Agreement (Sage Therapeutics, Inc.)", "score": 32.1485284052, "published": true}], "snippet_links": [{"key": "phase-4", "type": "definition", "offset": [10, 17]}, {"key": "required-study", "type": "definition", "offset": [18, 32]}], "hash": "7204291b223a475518db6d72608b8159", "id": 9}, {"snippet": "means a human clinical trial, conducted following Marketing Authorization for the Licensed Product in a particular indication, the principal purpose of which is to monitor the long term efficacy and safety in patients being studied with the Licensed Product in such indication or a related indication (including drug-drug interaction, dose-response, schedule of administration and/or duration, use of the drug in other patient populations or other stages of the disease, safety studies and/or other studies designed to support use under the approved indication) as further described in 21 C.F.R. \u00a7312.21, or similar clinical study in a country other than the United States.", "size": 2, "samples": [{"hash": "jk4mEqBlMyN", "uri": "/contracts/jk4mEqBlMyN#phase-4-study", "label": "License and Collaboration Agreement (Lexicon Pharmaceuticals, Inc.)", "score": 25.9746748802, "published": true}, {"hash": "dgZyBIVphrc", "uri": "/contracts/dgZyBIVphrc#phase-4-study", "label": "License and Collaboration Agreement (Lexicon Pharmaceuticals, Inc./De)", "score": 25.8459958932, "published": true}], "snippet_links": [{"key": "human-clinical-trial", "type": "definition", "offset": [8, 28]}, {"key": "marketing-authorization", "type": "clause", "offset": [50, 73]}, {"key": "licensed-product", "type": "clause", "offset": [82, 98]}, {"key": "purpose-of", "type": "clause", "offset": [141, 151]}, {"key": "long-term", "type": "clause", "offset": [176, 185]}, {"key": "and-safety", "type": "clause", "offset": [195, 205]}, {"key": "schedule-of", "type": "definition", "offset": [350, 361]}, {"key": "other-studies", "type": "clause", "offset": [493, 506]}, {"key": "approved-indication", "type": "definition", "offset": [541, 560]}, {"key": "clinical-study", "type": "clause", "offset": [616, 630]}, {"key": "the-united-states", "type": "definition", "offset": [655, 672]}], "hash": "deec93b5cde0e96e1553536ac7af20bb", "id": 10}], "next_curs": "CloSVGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjYLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIWcGhhc2UtNC1zdHVkeSMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"snippet": "means any study or data collection effort in respect to any Product for a particular Indication that is initiated after receipt of Regulatory Approval for such Product for such Indication.", "title": "Phase 4 Study", "size": 55, "id": "phase-4-study", "examples": ["Aptalis shall provide its comments to Strakan within fifteen (15) days after receiving a single Protocol for a <strong>Phase 4 Study</strong> and thirty (30) days after receiving multiple Protocols for a <strong>Phase 4 Study</strong>, and shall notify Strakan within such time period(s) whether or not it approves the respective Protocol(s), provided that such approval will not be unreasonably withheld, conditioned or delayed.", "Aptalis shall prepare a design and protocol(s) for any <strong>Phase 4 Study</strong> it or its sublicensees may propose (collectively, regardless of the preparer, including those prepared under Section 4.2.2, a \u201cProtocol\u201d) to carry out, and will submit each such Protocol to Strakan for its review, comment and approval.", "During the Term, Strakan will submit each Protocol for a <strong>Phase 4 Study</strong> it or its licensees may propose to carry out in respect of the Product outside of the Territory to Aptalis for its review, comment and approval.", "Strakan shall provide its comments to Aptalis within fifteen (15) days after receiving a single Protocol for a <strong>Phase 4 Study</strong> and thirty (30) days after receiving multiple Protocols for a <strong>Phase 4 Study</strong>, and shall notify Aptalis within such time period(s) whether or not it approves the respective Protocol(s), provided that such approval will not be unreasonably withheld, conditioned or delayed.", "Distributor shall be responsible for, at its sole cost and expense, in conducting and completing Phase 4 Studies (including any such <strong>Phase 4 Study</strong> that is required to be repeated as a result of a failure by Distributor to meet FDA standards for reviewability or are otherwise aborted by Distributor) in accordance with (a) professional standards and practices, (b) all applicable Laws and (c) the timeline provided in the First NDA or any extensions agreed to by the FDA and the development plan."], "related": [["phase-i-study", "Phase I Study", "Phase I Study"], ["phase-3-study", "Phase 3 Study", "Phase 3 Study"], ["phase-4-clinical-trial", "Phase 4 Clinical Trial", "Phase 4 Clinical Trial"], ["phase-ii-clinical-study", "Phase II Clinical Study", "Phase II Clinical Study"], ["phase-iii-study", "Phase III Study", "Phase III Study"]], "related_snippets": [], "updated": "2025-07-06T21:58:41+00:00"}, "json": true, "cursor": ""}}